Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use| Receiving market recognition! Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
Jan 27,2022
Happy Chinese New Year!
Happy Chinese New Year!
More
Happy Chinese New Year!
Jan 24,2022
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
On December 28, 2021, Hangzhou DAC Biotechnology Co., Ltd. (DAC Biotech) DXC007 project was successfully approved for clinical trials. DXC007 is the fourth ADC drug approved for clinical use by DAC Biotech, and it is also the fourth ADC drug that Shanghai Medicilon Inc. (Medicilon) to help DAC Biotech successfully getting approval.
More
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
More
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Jan 10,2022
Bao Pharmaceutical and Medicilon reached a strategic collaboration
On December 17, 2021, Shanghai Bao Pharmaceutical Co., Ltd. (Bao) and Shanghai Medicilon Inc. (Medicilon) signed an innovative drug IND R&D service strategy collaboration agreement.
More
Bao Pharmaceutical and Medicilon reached a strategic collaboration
Jan 04,2022
Recording the Growth of Medicilon in 2021
This year, Medicilon, with persistent belief, courageously and innovatively, pursued quality, and gave birth to the power of joint growth. Today, we take you to review the 2021 and witness the growth and progress of Medicilon!
More
Recording the Growth of Medicilon in 2021
Dec 20,2021
Receiving market recognition! Medicilon won the 2020 "Golden Bull Science and Technology Innovation Award"
More
Receiving market recognition! Medicilon won the 2020
Nov 24,2021
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Recently, the “2021 Yangpu Service Trade Digital Transformation Forum” under the guidance of the Shanghai Municipal Commission of Commerce and the People’s Government of Yangpu
More
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project
Nov 24,2021
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
On November 16, the “2021 Jiemian Health Forum” hosted by Shanghai United Media Group and Jiemian News was successfully held.  As a major part of
More
Dr. Chunlin Chen was Awarded the 2021 Super CEO of the Pharmaceutical and Health Industry
Nov 24,2021
Medicilon is Included in the MSCI China Index!
On the November 12th, the international index compilation company MSCI announced the results of the November quarterly index review.  Shanghai Medicilon Inc. (stock code: 688202.SH)
More
Medicilon is Included in the MSCI China Index!
Oct 21,2021
Medicilon was Awarded The "Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise"
From October 19-21, 2021, a grand event that has attracted the attention of the national pharmaceutical industry, “2021 Nanjing International Summit on Innovation and Investment
More
Medicilon was Awarded The
Oct 21,2021
Medicilon Symposium – "Preclinical Development Strategy of Innovative Drugs Driven by Translational Medicine" was Successfully Held
The 4th Annual Precision Medicine and Immuno-Oncology China Summit 2021 (PMIO China 2021) was successfully held in Zhangjiang, Shanghai recently.  Shanghai Medicilon Inc. (Medicilon) and
More
Medicilon Symposium –
Oct 18,2021
The Internationalization Trend of Chinese Pharmaceutical Companies and AI R&D Innovation Forum
Two forum themes, an inaugural meeting of Zhangjiang AI New Drug R&D Alliance Establishment, three keynote speeches, three rounds of roundtable discussion, a gathering of
More
The Internationalization Trend of Chinese Pharmaceutical Companies and AI R&D Innovation Forum